arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cocrystal Pharma, Inc.

COCP
$1.00 ▼ -0.09 (-8.26%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cocrystal Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $13.8M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -240.9% ↘
FCF / Share $-0.18 ↘
Trailing P/E —
Price / Book 13.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$105.00K
↓ -53.3% —
Net Income Profit after all expenses
$-2.30M
— +0.1% —
Operating Margin Operating profit as % of sales
-287.5%
↑ +32.4% —
FCF / Share Free cash flow per share
$-0.18
↓ -7.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
6
Cash Quality →
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 17 years · 65 quarters